1. Introduction {#sec1-ijms-21-05077}
===============

Leukemia is a malignant clonal disease of hematopoietic stem cells that can be divided into acute and chronic types. At present, these hematological cancers are the 10th most common cause of death in the world \[[@B1-ijms-21-05077]\]. Chronic myeloid leukemia (CML) is among the chronic leukemia types, and accounts for about 15--20% of all cases of leukemia in diagnosed patients \[[@B2-ijms-21-05077]\]. The survival rate of many CML patients has been greatly improved after treatment with tyrosine kinase inhibitors such as imatinib and nilotinib. Nevertheless, the appearance of resistance can be a serious problem in the treatment of CML \[[@B3-ijms-21-05077]\]. Therefore, it is important to develop new anticancer agents with different molecular targets or mechanisms of action for the treatment of CML. As a class of anticancer compounds, acridines and acridones have generally shown good cytotoxic or anticancer activity against acute and chronic leukemia cells \[[@B4-ijms-21-05077],[@B5-ijms-21-05077],[@B6-ijms-21-05077]\]. For instance, amsacrine (*m*-AMSA) has been used clinically in a number of countries for the treatment of acute leukemia \[[@B7-ijms-21-05077],[@B8-ijms-21-05077]\].

Among a new series of acridones synthesized previously \[[@B4-ijms-21-05077]\], it was discovered that *N*-\[2-(dimethylamino)ethyl\]-1-\[(3-methoxybenzyl)amino\]-5-nitro-9-oxo-9,10-dihydro-acridine-4-carboxamide (**8q**) significantly induces mitochondrial-mediated apoptosis and targets the PI3K/AKT/FOXO1 pathway in human acute lymphoblastic leukemia CCRF-CEM cells \[[@B9-ijms-21-05077]\]. Interestingly, it was also found that **8q** has potent nanomolar cytotoxic activity against human chronic myelogenous leukemia K562 cells. At the same time, this molecule showed a relatively low level of toxicity based on other in vitro data. Moreover, in silico calculations showed that **8q** conforms to Lipinski's rule of five, and is predicted to have good pharmacokinetic properties. However, the anti-chronic leukemia mechanism of action for this compound is still unclear. Metabolomics is a tool that can be used to effectively study the mechanisms of anti-cancer drugs, due to the impact of the cancer on cellular metabolism. Herein, a sensitive and accurate ultra-performance liquid chromatography/time-of-flight mass spectrometry (UPLC/Q-TOF MS) instrument was used to conduct the metabolomics profiling of chronic myelogenous leukemia K562 cells treated with the benzyl acridone analogue **8q**. Furthermore, molecular biology methods, homology modeling and molecular docking strategies were employed in this study to further investigate the possible anti-leukemia mechanism for this molecule.

2. Results {#sec2-ijms-21-05077}
==========

2.1. Multivariate Statistical Analysis and Changes in Metabolites {#sec2dot1-ijms-21-05077}
-----------------------------------------------------------------

Metabolomics was used to study the possible mechanism of action for **8q** on K562 cells. The chemical structure of **8q** is shown in [Figure 1](#ijms-21-05077-f001){ref-type="fig"}A. At first, the MTT experiment was conducted to evaluate the optimal drug concentration to use for the metabolomics study. K562 cells were treated with different concentrations of **8q** (0--2.5 μM) for 24 h ([Figure S1](#app1-ijms-21-05077){ref-type="app"}). When the concentration of **8q** was 0.5 μM, the cell viability was about 80%, and was deemed suitable for metabolomics research. UPLC/Q-TOF MS was used to study the changes in metabolic profiles between treated and untreated cells. As shown in [Figure 1](#ijms-21-05077-f001){ref-type="fig"}B,C, the respective base peak intensity (BPI) chromatograms had significant differences after **8q** treatment in both positive and negative MS detection modes. It is noteworthy that a high concentration of **8q** was detected in **8q**-treated cells, which indicated that **8q** can enter the cell membrane and is not immediately metabolized. By principal component analysis (PCA, [Figure 1](#ijms-21-05077-f001){ref-type="fig"}D,E), it was shown that the metabolites of the control (DMSO) and **8q**-treated group were obviously separated along the first principal component. In addition, the QC samples were tightly clustered in the middle of PCA scores, indicating the stability of the system throughout the experimental study. Therefore, these results show that the cellular metabolic phenotypes were significantly changed after treatment with **8q**. Next, the different metabolites between control and **8q**-treated group were assessed by independent t-test and false discovery rate. The q value was found to be less than 0.05, which indicated that there were significant differences between the two groups, and the corresponding metabolites were selected as potential biomarkers. A total of 119 significantly changed metabolites were identified in different ion modes, including 33 metabolites in the positive ion mode and 86 metabolites in the negative ion mode. Potential biomarkers were identified based on HR-MS spectra and MS/MS fragments, and compared with the corresponding standards in the database (HMDB, METLIN and lipid map). Metabolites in positive and negative ion modes are summarized in [Table 1](#ijms-21-05077-t001){ref-type="table"} and [Table 2](#ijms-21-05077-t002){ref-type="table"}, respectively. The results of matched MS/MS spectra metabolites have also been appended in [Tables S1 and S2](#app1-ijms-21-05077){ref-type="app"}.

2.2. Metabolic Pathway Analysis {#sec2dot2-ijms-21-05077}
-------------------------------

Changes in metabolic pathways caused by **8q**-treated cells were analyzed by the available online tools Biochemical Pathways (<http://biochemical-pathways.com>) and MetaboAnalyst 3.0 (<http://www.metaboanalyst.ca>). As shown in [Figure 2](#ijms-21-05077-f002){ref-type="fig"}A,B, the metabolic pathways disturbed by **8q** mainly included purine metabolism, alanine, aspartate and glutamate metabolism, arginine and proline metabolism, glycerophospholipid metabolism, [d]{.smallcaps}-glutamine and [d]{.smallcaps}-glutamate, aminoacyl-tRNA biosynthesis and glutathione metabolism. Purines supply the essential synthesis substrates for DNA and RNA \[[@B10-ijms-21-05077]\], and purine metabolism is often abnormally increased in tumor cells for rapid growth and proliferation that mainly affects the G1 phase of the cell cycle \[[@B11-ijms-21-05077]\]. Amino acids are essential for the synthesis of proteins and aminoacyl tRNA that are also especially important in the G1 phase \[[@B12-ijms-21-05077],[@B13-ijms-21-05077]\]. The metabolites here detected in five amino acid (alanine, aspartate, glutamate, arginine, and proline) metabolic pathways are also involved in aminoacyl-tRNA biosynthesis \[[@B14-ijms-21-05077]\]. As shown in [Tables S1 and S2](#app1-ijms-21-05077){ref-type="app"}, it was observed that the concentrations of [l]{.smallcaps}-glutamine, [l]{.smallcaps}-aspartate, [l]{.smallcaps}-leucine, [l]{.smallcaps}-proline and [l]{.smallcaps}-glutamate were all decreased after **8q** treatment. Hence, it was speculated that aminoacyl-tRNA biosynthesis was inhibited. Aminoacyl-tRNA biosynthesis is occurring at the G1 phase, as catalyzed by tRNA synthase \[[@B15-ijms-21-05077]\]. When tRNA synthase is inhibited, the aminoacyl-tRNA biosynthesis is blocked and cells will arrest in the G1 phase. Therefore, flow cytometry analysis can be used for further investigating the effect of **8q** on the cell cycle based on the above results.

2.3. **8q** Effectively Triggered G1 Cell Cycle Arrest in K562 Cells {#sec2dot3-ijms-21-05077}
--------------------------------------------------------------------

After the treatment of K562 cells with **8q** at 200 nM, 500 nM and 800 nM for 48 h, the cells were found to be arrested in the G1 phase of the cell cycle in a concentration-dependent manner. As shown in [Figure 2](#ijms-21-05077-f002){ref-type="fig"}C,D, the cell population in G0/G1 increased from 37.7% in untreated cells to 45.4%, 56.6% and 65.8% in the cells treated with **8q** at 200 nM, 500 nM and 800 nM, respectively. That is, the data show that treatment with **8q** results in G1 cell cycle arrest in K562 cells.

2.4. **8q** Showed Concentration-Dependent Inhibition of the Phosphorylation of the CDK4/6 Substrate Rb {#sec2dot4-ijms-21-05077}
-------------------------------------------------------------------------------------------------------

CDK4/6 is a specific protein of the G1 phase that binds with cyclin D to form a complex, promotes phosphorylation of target retinoblastoma-associated protein (Rb), and then allows the cell cycle to enter the S phase \[[@B16-ijms-21-05077]\]. The phosphorylation of Rb is required for the G1-S transition of the cell cycle. Therefore, selective inhibition of Rb phosphorylation can cause the arrest of the cell cycle in G1 phase. As shown in Western blots ([Figure 3](#ijms-21-05077-f003){ref-type="fig"}A,B), **8q** (200--800 nM) significantly inhibits CDK 4/6-mediated phosphorylation of Rb, and the expression of Rb protein increased slightly, in a concentration-dependent manner. In addition, the level of cyclin D1 in K562 cells also decreased in a concentration-dependent manner, upon 48 h treatment with **8q**. Meanwhile, the level of CDK4 was found to increase dramatically. It may be that **8q** affects the formation of CDK4 and cyclin D1 complexes, which is the key step to regulate Rb \[[@B17-ijms-21-05077],[@B18-ijms-21-05077]\]. Accordingly, based on the results of the Western blotting and cell cycle analysis, it is suggested that **8q** effectively triggers G1 cell cycle arrest in K562 cells by inhibiting CDK4/6-mediated phosphorylation of Rb.

2.5. Homology Modeling of CDK4/6 Protein and Molecular Docking {#sec2dot5-ijms-21-05077}
--------------------------------------------------------------

CDK4/6 inhibitors inhibit the progression of cancer cells from G1 to S phase and trigger G1 cell cycle arrest by selectively inhibiting the function of CDK4/6 \[[@B19-ijms-21-05077]\]. After metabolomics and molecular biology studies performed here revealed that the benzyl acridone **8q** might be a CDK4/6 inhibitor that down-regulates the phosphorylation level of downstream protein Rb, further studies were designed to evaluate this hypothesis. Therefore, the binding interactions between **8q** and CDK4/6 were analyzed in silico by homology modeling and molecular docking. Some CDK4 X-ray crystal structures have been obtained and reported, but all of them are in an inactive state in which the activation loop flaps over and partially closes the active site. CDK6 is a homologous protein of CDK4 with a high percentage of residue identity (71.3%) and similar physiological function. Homology modeling was used to build an active CDK4 structure ([Figure S2](#app1-ijms-21-05077){ref-type="app"}) according to a reported active CDK6 crystal structure (PDB ID: 2EUF). When docked in the model system, **8q** formed several hydrogen (H) bonds with CDK4. It had two H bonds with Val96 in the hinge region, which are conserved H bonds among known CDK4 inhibitors. The nitro group also formed one H bond with Asp158, the methoxy oxygen atom formed one H bond with Lys22, and the *N*,*N*-dimethylethylenediamine group formed another two H bonds with Glu144 and Asn145 ([Figure 4](#ijms-21-05077-f004){ref-type="fig"}A). The planar acridone ring was inserted into the active site, with its *N*,*N*-dimethylethylenediamine group extending to the negatively charged surface of CDK4 ([Figure 4](#ijms-21-05077-f004){ref-type="fig"}B). The docking result showed that **8q** is predicted to have a good complementary interaction with CDK4.

2.6. **8q** Significantly Induced Apoptosis in K562 Cells {#sec2dot6-ijms-21-05077}
---------------------------------------------------------

The work previously reported showed that **8q** has a strong antiproliferative activity that was expected to lead to apoptosis, as shown in vitro using K562 cells \[[@B9-ijms-21-05077]\]. In order to evaluate this hypothesis, a flow cytometry assay (Annexin V-FITC/PI) was conducted in K562 cells, as shown in [Figure 5](#ijms-21-05077-f005){ref-type="fig"}. The upper right-hand quadrants (Q2) showed the late stage of apoptotic or necrotic cells. The lower right-hand quadrants (Q3) showed the early stage of apoptotic cells. K562 cells were treated with **8q** at the concentrations of 0, 200, 500 and 800 nM for 48 h. As the concentration of **8q** increased, the percentage of apoptotic cells increased from 6.49% to 41.90%. In addition, an Annexin V-FITC/PI kit assay was conducted in K562 cells, as shown in [Figure S3](#app1-ijms-21-05077){ref-type="app"}. Annexin V-FITC can recognize early apoptotic cells and show green fluorescence. Propidium iodide (PI) was used to identify late apoptotic and necrotic cells, showing red fluorescence. The K562 cells were treated with **8q**, at concentrations of 0, 200, 500 and 800 nM for 48 h. Dimethyl sulfoxide (DMSO) was used as the negative treatment control. As the concentration of **8q** was incremented, the number of early apoptotic cells increased significantly. The early apoptosis of K562 cells was detected, starting at 200 nM of **8q**, the lowest concentration tested. When the concentration of **8q** was 800 nM, the number of late apoptotic cells also increased significantly. Additionally, the number of late apoptotic cells and necrotic cells also increased in a concentration-dependent manner. However, the trend of late apoptotic and necrotic cells was not as obvious as compared with that of early apoptotic cells. Therefore, it was concluded that **8q** effectively induces K562 cells apoptosis in a concentration-dependent manner. However, the late apoptosis and necrosis induced by **8q** could not be well distinguished in this test. Therefore, apoptosis and necrosis analyses were carried out using Hoechst 33342/PI kit. Similarly, it was confirmed that **8q** significantly induces apoptosis in K562 cells from the results shown in [Figure S4](#app1-ijms-21-05077){ref-type="app"}. Hoechst 33342 (purchased from Beyotime Biotechnology, Shanghai, China) can be used to recognize apoptotic cells (blue fluorescence), and PI is used to identify necrotic cells (red fluorescence). Taking the above into consideration, the results suggested that **8q** induces apoptosis and inhibits the proliferation of K562 cells.

2.7. **8q** Induced Apoptosis through the Caspase Pathway {#sec2dot7-ijms-21-05077}
---------------------------------------------------------

Apoptotic pathways are divided into mitochondria-mediated (intrinsic) and exogenous apoptotic pathways \[[@B20-ijms-21-05077]\]. Caspase family proteins, such as Caspase-9, 8 and 3, are the main executors of apoptosis, and the activity changes of different caspase isoforms can distinguish the apoptosis pathways \[[@B21-ijms-21-05077],[@B22-ijms-21-05077]\]. From the results ([Figure 6](#ijms-21-05077-f006){ref-type="fig"}A,B), we can see that **8q** activated Caspase-9, 8 and 3 proteins in a concentration-dependent manner. These results suggested that **8q** induced K562 cells apoptosis through both mitochondria-mediated and exogenous apoptotic pathways. Z-VAD-FMK is a pan-caspase inhibitor. When K562 cells were pretreated with Z-VAD-FMK (10 μM), **8q** (800 nM) could not induce the up-regulation of cleaved Caspase-3 when compared with those without Z-VAD-FMK pretreatment ([Figure 6](#ijms-21-05077-f006){ref-type="fig"}C,D). Therefore, these results demonstrate that apoptosis is the main cell death mechanism upon **8q** treatment in K562 cells.

2.8. In Vitro Anti-Proliferation Activity of KCL-22 and K562/ADR Cells {#sec2dot8-ijms-21-05077}
----------------------------------------------------------------------

In order to verify the inhibitory activity of compound **8q** on other chronic myeloid leukemia cells, we selected KCL-22 cells for the MTT assay. In addition, human leukemia K562 adriamycin-resistant cells (K562/ADR) were also selected in the assay, to investigate whether **8q** had in vitro anti-proliferative activity against drug-resistant cell line. The results were shown in [Figure 7](#ijms-21-05077-f007){ref-type="fig"}. It is worth noting that **8q** showed obvious anti-proliferative activity against KCL-22 cells and K562/ADR cells, with IC~50~ values of 520 nM and 250 nM after 48 h treatment. In addition, when these cell lines were treated with **8q** for 72 h, we found that the inhibitory activity was significantly increased, and the IC~50~ values were 90 nM and 170 nM, respectively. Therefore, it is suggested that compound **8q** not only had good in vitro anti-proliferative activity against other CML cells, but also had significant inhibitory activity against drug-resistant leukemia cells. Thus, **8q** may be a promising hit compound in the treatment of CML.

3. Discussion {#sec3-ijms-21-05077}
=============

Our previous work reported that the new methoxybenzyl 5-nitroacridone **8q** exhibits strong anti-proliferation activity against human chronic myelogenous leukemia K562 cells and had relatively low toxicity in vitro. In this study, through the analysis of metabolic principal components and metabolic pathways, it was found that **8q** induced significant changes in the metabolites of K562 cells, and that most of the metabolic pathways affected the G1 phase of cancer cells, such as purine metabolism, aminoacyl-tRNA biosynthesis, and so on. In addition, a concentration-dependent accumulation of cells in G1 phase was observed by cell cycle analysis after treatment with **8q**. CDK4/6 is a specific protein of the G1 phase that binds with cyclin D to form a complex, promotes the phosphorylation of target Rb protein, and then allows the cell cycle to enter the S phase. Therefore, the phosphorylation of Rb is required for the G1-S transition of the cell cycle. Western blot analysis showed that the expression levels of phosphorylated Rb and cyclin D1 significantly decreased in a concentration dependent manner after **8q** treatment for 48 h, in addition, **8q** obviously increased the expression level of CDK4 in K562 cells with the increase of the drug's concentration. Furthermore, the likely binding interactions between **8q** and CDK4/6 were clarified by in silico molecular docking studies. Therefore, these results suggest that **8q** can effectively trigger G1 cell cycle arrest in K562 cells by inhibiting CDK4/6-mediated phosphorylation of Rb.

Cell cycle arrest is often associated with cell apoptosis. This study continued to investigate whether **8q** can induce K562 cells apoptosis and further verify which apoptotic pathway it followed. Apoptosis and necrosis detection assay showed that the percentage of apoptotic cells increased from 6.49% to 41.90% as the concentration of **8q** increased. It is suggested that **8q** significantly induces cell apoptosis and inhibits the proliferation of K562 cells. Western blotting results further displayed that **8q** induced K562 cells apoptosis through both mitochondria-mediated and exogenous apoptotic pathways. In addition, we observed that, after pretreating K562 cells with Z-VAD-FMK (a pan-caspase inhibitor), the effect of **8q** on the cleavage of Caspase-3 disappeared, suggesting that **8q** induced apoptosis through the caspase pathway. Furthermore, the MTT assay showed that **8q** not only had good in vitro anti-proliferative activity against other CML cells (KCL-22 cells), but also had significant inhibitory activity against drug-resistant leukemia cells (K562/ADR cells).

In conclusion, the reported results suggest that **8q** can effectively trigger G1 cell cycle arrest and induce cell apoptosis in K562 cells by inhibiting CDK4/6-mediated phosphorylation of Rb. This study accordingly provides new information and guidance for the application of new acridone derivatives to be developed for the potential treatment of CML.

4. Materials and Methods {#sec4-ijms-21-05077}
========================

4.1. Reagents and Materials {#sec4dot1-ijms-21-05077}
---------------------------

*N*-(2-(dimethylamino)ethyl)-1-((3-methoxybenzyl)amino)-5-nitro-9-oxo-9,10-dihydro-acridine-4-carboxamide (**8q**) was synthesized by Zhang \[[@B4-ijms-21-05077]\]. Z-VAD-FMK (a pan-caspase inhibitor) was purchased from Selleck (Shanghai, China). Human chronic myelogenous leukemia K562 cells were purchased from the Chinese Academy of Sciences Cell Bank. Human chronic myelogenous leukemia KCL-22 cells and K562 adriamycin-resistant cells (K562/ADR) were purchased from Zhen Shanghai and Shanghai Industrial Co., Ltd. (China). Iscove's Modified Dubecco's Medium (IMDM) and Fetal bovine serum (FBS) was purchased from Hyclone (Logan, Utah, USA). Cleaved Caspase-3 antibodies were purchased from Cell Signaling Technology, Inc. (Boston, Massachusetts, USA), Cleaved Caspase-9, 8 antibodies were purchased from Wuhan SanYing Co., Ltd. (Wuhan, China); other antibodies we used in this study were purchased from Beyotime Biotechnology (Shanghai, China). Annexin V-FITC/PI apoptosis detection kit, apoptosis and necrosis assay kit and cell cycle and apoptosis analysis kit were purchased from Beyotime Biotechnology (Shanghai, China). Formic acid (HPLC) was purchased from Tedia (Ohio, USA). Acetonitrile (HPLC) and methanol (HPLC) were purchased from Fisher (Waltham, Massachusetts, USA).

4.2. Apoptosis and Necrosis Detection Assay {#sec4dot2-ijms-21-05077}
-------------------------------------------

Cell early and late apoptosis were detected using the Annexin V-FITC/propidium iodide (PI) apoptosis detection kit. Cell apoptosis and necrosis were detected using an apoptosis and necrosis assay kit (Hoechst 33342 and PI). Both two assays were detected after 0--800 nM of **8q** treatment for 48 h. The experimental procedure was followed according to the instructions of the manufacturer. Axio Observer 5 with an Apotome fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany) was used to observe the effect of **8q** on the apoptosis and necrosis of K562 cells.

4.3. Metabolomics Analysis Conditions {#sec4dot3-ijms-21-05077}
-------------------------------------

The extraction of samples and the detection of metabolites using a UPLC/Q-TOF MS method were completed as previously described \[[@B9-ijms-21-05077]\]. In this study, K562 cells were exposed to 500 nM of **8q**.

4.4. Flow Cytometric Analysis for Cell Cycle {#sec4dot4-ijms-21-05077}
--------------------------------------------

For cell cycle analysis, K562 cells were seeded in a six-well plate and incubated for 12 h following treated with graded concentrations of **8q** for 48 h. Cells were collected and washed twice by phosphate buffered saline (PBS), then fixed in ice cold 70% ethanol. Cells were stained with 4 mg/mL PI and 0.1 mg/mL RNaseA in PBS. After incubation in the dark at room temperature for 30 min, samples were subjected to flow cytometric analysis.

4.5. Western Blotting {#sec4dot5-ijms-21-05077}
---------------------

K562 cells were cultured in 6 cm dishes, followed by treatment with **8q** for different concentration periods for 48 h. Proteins were separated by electrophoresis on an 8--12% Sodium dodecyl sulfate (SDS) polyacrylamide gel and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 3% bovine serum albumin and then incubated with primary antibodies, followed by a horseradish peroxidase conjugated secondary antibody and detected by the Luminescence Image Analyzer Tanon 5200.

4.6. In Vitro Anti-Proliferative Assay {#sec4dot6-ijms-21-05077}
--------------------------------------

KCL-22 cells and K562/ADR cells were seeded into 96-well plates at 0.8--1.6 × 10^4^ cells/well, treated with compound **8q**. After 48 or 72 h treatment, the cells were incubated with 15 mL MTT (3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide from Sigma) solution (5 mg/mL) for 4 h at 37 °C with 5% CO~2~. The formazan precipitates were dissolved in 100 mL DMSO. At 490 nm, the absorbance was measured by InfiniteM1000 PRO (TECAN).

4.7. Homology Modeling {#sec4dot7-ijms-21-05077}
----------------------

The amino acid sequence of homo sapiens CDK4 (GI: 49457488) was retrieved from the NCBI website. The crystal structure of homo sapiens CDK6 \[[@B23-ijms-21-05077]\] in active form was retrieved in protein data bank serve (PDB ID: 2EUF), and employed as the template to build the 3D structure of the active form of CDK4. The sequence of the template and CDK4 were aligned, having 71.3% sequence identity. A reliable homology model of CDK4 was predicted using Molecular Operating Environment (MOE, Chemical Computing Group, Montreal, QC, Canada). Protein geometry was checked by Ramachandran plot.

4.8. Molecular Docking {#sec4dot8-ijms-21-05077}
----------------------

The molecular docking was performed on Gold suite v5.2.2 (Cambridge Crystallographic Data Centre Software Ltd., Cambridge, UK), with default genetic algorithm settings \[[@B24-ijms-21-05077],[@B25-ijms-21-05077]\]. Docking was performed without a reference ligand. The active site residues, Ile12, Gly13, Val20, Lys22, Ala33, Val72, Arg73, Leu74, Phe93\~Thr102, Glu144, Asn145, Leu147, Ala157 and Asp158, were selected as a binding pocket. Gold Score was used as the fitness function for selecting the best docked conformation of the ligand.
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![LC-MS based metabolomics study of K562 cells treated with **8q**. (**A**) Chemical structure of **8q**; (**B**) base peak intensity (BPI) chromatograms obtained from control and treated K562 cell extracts in positive ion mode; (**C**) and negative ion mode; (**D**) PCA of positive ion mode data; (**E**) PCA of negative ion mode data.](ijms-21-05077-g001){#ijms-21-05077-f001}

![(**A**) Metabolic pathways altered by cell treatment with **8q**. (**B**) Quantitative analysis of the impact of **8q** on metabolic pathways. (**C**) Flow cytometric analysis of **8q** induction of G0/G1 phase cell cycle arrest in K562 cells. K562 cells were treated with **8q** at the indicated concentrations for 48 h. (**D**) Cell cycle phase analysis of K562 cells treated with **8q**.](ijms-21-05077-g002){#ijms-21-05077-f002}

![(**A**) **8q** inhibited CDK 4/6-mediated phosphorylation of Rb; (**B**) The densitometry of proteins performed on the Western blotting of A, \* *p* \< 0.05; \*\* *p* \< 0.01.](ijms-21-05077-g003){#ijms-21-05077-f003}

![(**A**) CDK4 is depicted in grey cartoon form with grey stick residues involved in hydrogen bonding, and **8q** is shown as a cyan stick model. Oxygen atoms and nitrogen atoms are depicted in red and blue, respectively. Hydrogen bonds are shown as red dashed lines. (**B**) CDK4 is represented in electrostatic surface form, with blue and red indicating positive and negative charges respectively.](ijms-21-05077-g004){#ijms-21-05077-f004}

![**8q** induced apoptosis in K562 cells (48 h) at different concentrations (0, 200, 500, 800 nM). DMSO as a negative control.](ijms-21-05077-g005){#ijms-21-05077-f005}

![**8q** induced both mitochondria-mediated and exogenous apoptosis. (**A**) The expressions of caspase family proteins were determined after **8q** treatment; (**B**) The densitometry of caspase family proteins performed on the Western blotting of A, \*\* *p* \< 0.01; (**C**) The expressions of caspase-3 were determined after **8q** (800 nM) or Z-VAD-FMK (10 μM) treatment; (**D**) The densitometry of caspase-3 performed on the western blotting of C, \*\* *p* \< 0.01.](ijms-21-05077-g006){#ijms-21-05077-f006}

![Antiproliferative activity of **8q** against KCL-22 and K562-ADR cells.](ijms-21-05077-g007){#ijms-21-05077-f007}
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###### 

Summary of metabolites in positive ion mode.

  Ion Model                               Name       Ret. Time   *m*/*z*    ∆ppm                                                                                                   MS/MS                *q* Value   FC ^a^
  --------------------------------------- ---------- ----------- ---------- ------------------------------------------------------------------------------------------------------ -------------------- ----------- --------
  Positive ion mode                       Spermine   0.4484      203.2231   0                                                                                                      84.0; 112.1; 129.1   0.000       0.027
  Neurine                                 0.5467     104.105     19         104.1                                                                                                  0.000                0.225       
  [l]{.smallcaps}-Proline                 0.5739     116.0691    12         70.0; 116.0                                                                                            0.000                0.021       
  Adenosine 3′-monophosphate              0.5884     348.0696    2          136.0; 348.0                                                                                           0.000                0.034       
  Glutathione                             0.6219     308.09      3          58.9; 76.0; 84.0; 116.0; 130.0; 140.0; 144.0; 162.0; 179.0; 187.0; 215.0; 233.0; 245.0; 291.0; 308.0   0.000                con ^b^     
  3′-Keto-3′-deoxy-AMP                    0.6226     346.0473    21         136.0; 346.0                                                                                           0.000                0.001       
  Piperidine                              0.6272     86.0936     32         69.0; 86.1                                                                                             0.000                0.028       
  [l]{.smallcaps}-Leucine                 0.8145     132.1013    4          69.0; 86.0                                                                                             0.000                0.026       
  Piperidine                              0.8172     86.094      28         69.0; 86.0                                                                                             0.000                0.007       
  Xestoaminol C                           4.5328     230.2476    1          212.2; 230.2                                                                                           0.001                0.815       
  C16 Sphinganine                         4.6369     274.2741    0          256.2; 274.2                                                                                           0.003                con         
  PC(16:0/0:0)                            5.7318     496.3372    5          86.0; 184.0; 478.3; 496.3                                                                              0.000                0.097       
  PC(22:2/0:0)                            5.8967     576.4092    11         277.2; 559.3; 576.4                                                                                    0.000                0.239       
  PC(16:0/0:0)                            5.9447     496.3376    4          104.1; 184.0; 258.1; 313.2; 419.2; 478.3; 496.3                                                        0.000                0.487       
  PE(18:1/0:0)                            6.1807     480.3233    30         155.0; 339.2; 462.3; 480.3                                                                             0.000                0.668       
  PE(18:0/0:0)                            7.0864     482.3245    0          341.3; 462.2; 482.3                                                                                    0.000                0.214       
  PC(0:0/18:0)                            7.1339     524.3699    2          104.1; 184.0; 341.3; 506.3; 524.3                                                                      0.000                0.578       
  PC(20:1/0:0)                            7.3169     550.3867    0          104.1; 184.0; 532.3; 553.3                                                                             0.000                0.197       
  PC(18:0/18:2)                           8.8141     786.6016    1          184.0; 605.5; 786.6                                                                                    0.249                0.548       
  PC(18:1/18:1)                           9.2222     786.601     0          184.0; 522.3; 603.5; 786.6                                                                             0.024                0.297       
  PC(18:3/18:1)                           9.3872     782.571     2          184.0; 603.5; 782.5                                                                                    0.000                0.375       
  PC(18:1/18:1)                           9.4376     786.6019    1          184.0; 339.2; 504.3; 522.3; 786.6                                                                      0.035                0.172       
  13*E*-Docosenamide/13*Z*-Docosenamide   9.9366     338.3416    0          303.3; 321.3; 338.3                                                                                    0.025                1.613       
  PC(18:1/18:2)                           10.7816    784.5947    12         86.0; 184.0; 504.3; 784.5                                                                              0.000                0.381       
  PC(18:1/16:1)                           10.7869    758.5774    10         184.0; 504.3; 758.5                                                                                    0.013                0.279       
  PC(18:1/18:1)                           10.7904    786.6056    6          184.0; 603.5; 786.6                                                                                    0.035                0.440       
  PC(16:1/18:0)                           10.7926    760.5899    6          86.0; 184.0; 577.5; 760.5                                                                              0.231                0.617       
  PC(14:1/17:0)                           10.7938    718.5497    16         184.0; 577.5; 718.5                                                                                    0.010                0.338       
  PC(20:3/18:0)                           10.7944    812.64      29         184.0; 504.3; 812.6                                                                                    0.122                0.402       
  PC(P-16:0/15:1)                         10.7954    702.5472    5          184.0; 702.5                                                                                           0.100                0.559       
  SM(d18:1/16:0)                          10.7964    703.5721    3          86.0; 184.0;7 03.5                                                                                     0.023                0.181       
  PE(18:1/18:1)                           10.7979    744.5627    11         265.2; 603.5; 744.5                                                                                    0.003                0.365       
  PE(18:1/0:0)                            10.8012    480.3095    2          339.2; 480.3                                                                                           0.000                0.614       

Note: ^a^ FC means Fold change (**8q**/control); ^b^ con means control group.

ijms-21-05077-t002_Table 2

###### 

Summary of metabolites in negative ion mode.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ion Model                                                                             Name                          Ret. Time   *m*/*z*    ∆ppm                                                           MS/MS                                    *q* Value   FC ^a^
  ------------------------------------------------------------------------------------- ----------------------------- ----------- ---------- -------------------------------------------------------------- ---------------------------------------- ----------- --------
  Negative ion mode                                                                     UDP-glucose/UDP-D-galactose   0.5493      565.0425   9                                                              78.9; 96.9; 241.0; 323.0; 385.0; 565.0   0.000       0.002

  Uridine diphosphate-*N*-acetylglucosamine                                             0.5502                        606.0683    9          78.9; 158.9; 272.9; 282.0; 384.9; 403.0; 606.0                 0.000                                    0.002       

  ADP                                                                                   0.5611                        426.0179    9          78.9; 134.0; 158.9; 272.9; 328.0; 408.0; 426.0                 0.000                                    0.004       

  Inosine 5′-monophosphate (IMP)                                                        0.5714                        347.0376    6          78.9; 96.9; 347.0                                              0.000                                    0.011       

  5-Aminoimidazole-4-carboxamide-1-*β*-[d]{.smallcaps}-ribofuranosyl 5′-monophosphate   0.5799                        337.0528    7          78.9; 96.9; 337.0                                              0.000                                    0.007       

  [l]{.smallcaps}-Aspartic Acid                                                         0.5844                        132.0255    35         88.0; 114.0; 132.0                                             0.000                                    0.009       

  [l]{.smallcaps}-Glutamate                                                             0.5857                        146.0426    22         102.0; 128.0; 146.0                                            0.000                                    0.049       

  [d]{.smallcaps}-Glycerol 1-phosphate                                                  0.5858                        171.0083    11         78.9; 89.0; 171.0                                              0.000                                    0.012       

  Sulfuric acid                                                                         0.591                         96.9602     0          78.9; 96.9                                                     0.000                                    0.235       

  Adenosine monophosphate                                                               0.6116                        346.0515    12         78.9; 96.9; 211.0; 346.0                                       0.000                                    0.026       

  [l]{.smallcaps}-Glutamine                                                             0.6118                        145.0599    13         102.0; 128.0; 146.9                                            0.000                                    0.003       

  [l]{.smallcaps}-Leucine                                                               0.7127                        130.0842    24         130.0                                                          0.000                                    0.077       

  Cumanin                                                                               4.6125                        265.1467    8          96.9; 265.1                                                    0.007                                    0.143       

  Dehydroabietic acid                                                                   5.6388                        299.2017    0          299.2                                                          0.000                                    2.076       

  PE(P-16:0/0:0)                                                                        6.3388                        436.2828    1          153.0; 196.0; 239.2; 436.2                                     0.002                                    1.535       

  Arginyl-Glutamine                                                                     6.4253                        301.1607    7          217.0; 286.1; 301.1                                            0.000                                    2.691       

  Δ2-trans-Hexadecenoic Acid                                                            6.4529                        253.2172    0          84.5; 253.2                                                    0.012                                    2.286       

  Arachidonic Acid (peroxide free)                                                      6.7046                        303.2337    2          205.1; 259.2; 303.2                                            0.000                                    71.665      

  Arginyl-Gamma-glutamate                                                               6.8151                        301.1606    7          301.1                                                          0.000                                    2.560       

  PE(18:0/0:0)                                                                          7.2382                        480.3079    3          196.0; 283.2; 480.3                                            0.000                                    0.416       

  Petroselinic acid/Oleic Acid                                                          7.9889                        281.2483    1          281.2                                                          0.000                                    3.103       

  11*Z*,14*Z*-Eicosadienoic Acid                                                        8.4771                        307.2647    1          307.2                                                          0.000                                    7.295       

  Stearic acid                                                                          9.222                         283.2654    4          265.3; 283.2                                                   0.000                                    2.336       

  PI(20:5/18:1)                                                                         9.3598                        881.5158    3          241.0; 281.2; 881.5                                            0.000                                    2.836       

  cis-gondoic acid/\                                                                    9.3917                        309.2805    1          309.2                                                          0.000                                    5.116       
  2*E*-Eicosenoic acid                                                                                                                                                                                                                                           

  PS(18:0/19:1)                                                                         9.4136                        802.5604    0          283.2; 419.2; 701.5; 802.5                                     0.005                                    0.751       

  PS(18:0/18:1)                                                                         9.4246                        788.5407    5          152.9; 283.2; 419.2; 701.5; 788.5                              0.001                                    0.545       

  PG(18:1/22:6)                                                                         9.4363                        819.525     8          281.2; 327.2; 419.2; 819.5                                     0.000                                    0.516       

  PI(20:4/16:0)                                                                         9.5244                        857.5121    7          241.0; 303.2; 391.2; 553.2; 857.5                              0.000                                    3.782       

  PI(20:4/18:1)                                                                         9.5572                        883.5157    20         152.9; 222.9; 241.0; 303.2; 417.2; 579.2; 883.5                0.001                                    1.449       

  PG(18:3/18:1)                                                                         9.5579                        769.5007    2          152.9; 277.2; 281.2; 769.5                                     0.000                                    11.712      

  PI(16:1/18:1)                                                                         9.5732                        833.5135    6          152.9; 241.0; 253.2; 281.2; 389.2; 417.2; 579.2; 833.5         0.000                                    0.752       

  PG(20:3/18:1)                                                                         9.6053                        797.53      4          152.9; 281.2; 305.2; 765.6; 797.5                              0.000                                    0.330       

  PS(18:0/18:1)                                                                         9.6188                        788.5404    5          152.9; 281.2; 283.2; 417.2; 419.2; 701.5; 788.5                0.000                                    0.086       

  PG(18:1/20:4)                                                                         9.6202                        795.5092    11         281.2; 303.2; 417.2; 795.5                                     0.000                                    16.215      

  PI(18:1/18:2)                                                                         9.6278                        859.5297    5          152.9; 241.0; 279/2; 281.2; 415.2; 417.2; 577.2; 579.2;859.5   0.007                                    1.146       

  7,7-dimethyl-5,8-Eicosadienoic Acid                                                   9.6238                        335.2971    4          335.2                                                          0.000                                    5.874       

  PG(16:1/18:1)                                                                         9.6489                        745.4967    7          152.9; 253.2; 281.2; 389.2; 491.2; 673.5; 745.4                0.000                                    17.477      

  PI(20:2/20:4)                                                                         9.659                         909.5474    2          241.0; 303.2; 307.2; 439.2; 443.2; 909.5                       0.000                                    1.953       

  Nervonic acid                                                                         9.6611                        365.3426    0          365.3                                                          0.000                                    3.921       

  PG(18:2/18:1)                                                                         9.6761                        771.5117    8          152.9; 279.2; 281.2; 771.5                                     0.000                                    4.204       

  Docosanoic acid                                                                       9.7185                        339.3293    7          339.3                                                          0.000                                    3.146       

  PG(18:1/17:1)                                                                         9.7688                        759.5153    3          152.9; 267.2; 281.2; 759.5                                     0.000                                    8.753       

  PI(20:4/18:0)                                                                         9.7744                        885.546     4          223.0; 241.0; 283.2; 303.2; 419.2; 581.3; 885.5                0.000                                    2.928       

  PI(18:0/22:5)                                                                         9.7767                        911.5626    3          152.9; 241.0; 329.2; 419.2; 581.3; 607.3; 911.5                0.000                                    1.520       

  PG(18:1/15:0)                                                                         9.7803                        733.4986    5          281.2; 733.4                                                   0.000                                    3.943       

  PI(O-16:0/18:1)                                                                       9.8087                        821.5381    20         255.2; 281.2; 437.2; 745.5; 821.5                              0.018                                    1.521       

  PA(17:0/16:1)                                                                         9.8117                        659.4584    11         253.2; 659.4                                                   0.000                                    6.842       

  PI(18:1/18:1)                                                                         9.8177                        861.5442    6          78.9; 223.0; 241.0; 281.2; 417.2; 579.2; 792.5; 861.5          0.007                                    0.677       

  PG(18:1/18:1)                                                                         9.833                         773.5242    12         152.9; 241.2; 417.2; 509.2; 773.5                              0.031                                    1.315       

  PG(20:2/18:1)                                                                         9.84                          799.5471    2          152.9; 281.2; 307.2; 799.5                                     0.000                                    0.177       

  PG(20:4/18:0)                                                                         9.8432                        797.5334    0          152.9; 260.2; 283.2; 303.2; 419.2; 511.3; 797.5                0.000                                    51.407      

  5,9-hexacosadienoic acid                                                              9.8475                        391.3566    3          391.3                                                          0.001                                    2.517       

  PI(18:1/20:2)                                                                         9.8834                        887.5579    8          152.9; 223.0; 241.0; 307.2; 417.2; 443.2; 579.2; 887.5         0.000                                    0.308       

  PG(16:0/18:1)                                                                         9.8925                        747.5105    10         255.2; 281.2; 465.2; 747.5                                     0.000                                    0.437       

  PI(18:1/17:0)                                                                         9.9228                        849.5507    0          241.0; 281.2; 419.2; 567.3; 849.5                              0.001                                    1.593       

  PI(22:4/18:0)                                                                         9.9428                        913.5793    2          152.9; 283.2; 331.2; 419.2; 443.2; 581.3; 605.3; 913.5         0.013                                    1.158       

  PG(18:1/20:1)                                                                         9.9942                        801.5621    3          152.9; 281.2; 309.2; 728.5; 801.5                              0.000                                    0.162       

  PG(22:2/18:1)                                                                         9.9951                        827.5801    0          281.2; 335.2; 419.2;827.5                                      0.000                                    0.057       

  PI(18:0/18:1)                                                                         10.0446                       863.5568    10         152.9; 241.0; 281.2; 283.2; 417.2; 419.2; 581.3; 863.5         0.027                                    0.733       

  Lignoceric acid                                                                       10.0555                       367.3588    1          367.3                                                          0.000                                    7.465       

  PA(18:1/17:0)                                                                         10.0864                       687.4864    15         152.9; 281.2; 423.2; 687.4                                     0.000                                    10.392      

  PA(19:1/18:1)                                                                         10.0979                       713.4849    38         152.9; 253.2; 281.2; 417.2; 713.4                              0.000                                    4.158       

  PI(22:2/18:1)                                                                         10.1148                       915.599     2          152.9; 241.0; 417.2; 579.2; 915.5                              0.000                                    0.475       

  PI(20:2/18:0)                                                                         10.1387                       889.5771    4          223.0; 241.0; 283.2; 307.2; 419.2; 443.2; 581.3; 599.3         0.000                                    0.380       

  PG(18:0/18:1)                                                                         10.1847                       775.5441    6          152.9; 281.2; 283.2; 419.2; 493.2; 511.3; 775.5                0.001                                    0.789       

  PE(P-18:1/18:3)                                                                       10.2445                       722.5086    6          152.9; 281.2; 413.1; 417.2; 722.5                              0.002                                    0.404       

  PI(22:2/20:1)                                                                         10.4522                       943.6288    0          241.0; 445.2; 607.3                                            0.000                                    0.303       

  PS(18:0/18:1)                                                                         10.5039                       788.5415    4          152.9; 281.2; 283.2; 417.2; 419.2; 701.5; 788.5                0.020                                    0.212       

  PI(18:0/20:1)                                                                         10.5194                       891.5939    3          153.0; 223.0; 241.0; 283.2; 309.2; 419.2; 581.3; 891.5         0.003                                    0.020       

  PI(22:2/18:0)                                                                         10.5319                       917.6085    4          153.0; 223.0; 241.0; 335.2; 419.2; 581.3; 917.6                0.000                                    0.613       

  Arachidic Acid/Phytanic Acid                                                          10.5858                       311.2971    4          311.2                                                          0.000                                    2.173       

  13*Z*-Docosenoic Acid                                                                 10.6089                       337.3124    3          337.3                                                          0.000                                    2.192       

  Oleic Acid                                                                            10.8021                       281.2501    5          281.2                                                          0.001                                    1.746       

  PA(20:2/18:1)                                                                         10.8195                       725.4859    36         152.9; 281.2; 417.2; 462.3                                     0.011                                    0.607       

  PE(18:1/18:1)                                                                         10.8206                       742.5396    0          196.0; 281.2; 460.2; 478.2; 742.5                              0.003                                    0.334       

  PI(20:2/18:0)                                                                         10.8474                       889.5809    2          241.0; 283.2; 307.2; 889.5                                     0.008                                    0.570       

  PS(22:1/18:1                                                                          10.8657                       842.5978    7          281.2; 755.5; 842.5                                            0.000                                    0.147       

  PS(18:0/19:1                                                                          10.8682                       802.5587    2          152.9; 281.2; 419.2; 710.5; 715.2; 802.5                       0.000                                    0.420       

  PS(18:0/18:1)                                                                         10.8685                       788.5394    6          152.9; 283.2; 419.2; 701.5; 788.5                              0.000                                    0.365       

  PS(18:1/18:1)                                                                         10.8723                       786.5269    2          152.9; 281.2; 417.2; 699.4; 701.5; 786.5                       0.000                                    0.240       

  PS(18:0/22:6)                                                                         10.8727                       834.5257    3          283.2; 419.2; 463.2; 747.4; 834.5                              0.000                                    0.350       

  PS(18:1/16:0)                                                                         10.8735                       760.5147    1          152.9; 255.2; 281.2; 391.2; 673.5                              0.000                                    0.109       

  PI(20:4/18:0)                                                                         10.8741                       885.55      0          241.0; 419.2; 581.3; 885.5                                     0.000                                    2.550       

  PG(18:0/17:1)                                                                         10.8803                       761.5346    1          152.9; 283.2; 391.2; 419.2; 687.5; 761.5                       0.001                                    0.086       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: ^a^ FC means Fold change (**8q**/control).
